BioSpace News Archive

Evotec SE announced the opening of the company’s late-stage clinical and commercial biologics cGMP manufacturing facility 1 US) in Redmond, Washington.

Vensica Therapeutics, a clinical stage biopharmaceutical company, announced that it has signed a strategic collaboration agreement with Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins Vensica has licensed Merz’s botulinum neurotoxin A for needle-free use in urological procedures.

Researchers at Ben-Gurion University of the Negev are developing a novel therapeutic strategy for treating Inflammatory Bowel Diseases by sequestering inflammation-inducing molecules secreted by gut bacteria.

Bio-Thera Solutions, Ltd. announced the discovery of a broad-spectrum SARS-CoV-2 neutralizing antibody with the potential to treat COVID-19.

Punctal plugs are small-sized medical devices used to treat dry eye. Dry eye is a disease wherein patients are not able to keep the eye comfortable and healthy, as no sufficient tears are produced.

Radiation therapy or radiotherapy has emerged as a cost-effective cancer treatment modality and gained significance in reducing morbidity and mortality due to cancer.

Candidiasis is a kind of a fungal infection cause by any kind of Candida. When it attacks the mouth, it is usually known as thrush.

Photocure ASA reported Hexvix®/Cysview® revenues of NOK 88.9 million in the second quarter of 2021, and EBITDA of NOK 5.8 million, driven by growth in the U.S. segment and the continued successful launch in European markets reacquired in 2020.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,083,715 and U.S. Patent No. 11,083,716 covering the novel 3.0 mg three times daily cytisinicline dosing regimen.

Second Sight Medical Products, Inc. announces that the Company received a grant supplement from the National Institutes of Health to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprostheses.